(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
@ $37.88
発行日: 14 2月 2024 @ 23:30
リターン: -10.08%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 2.07 %
Live Chart Being Loaded With Signals
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...
Stats | |
---|---|
本日の出来高 | 189 853 |
平均出来高 | 477 452 |
時価総額 | 1.61B |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $-1.040 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.65 |
ATR14 | $0.0100 (0.03%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-26 | Deck Kelly | Sell | 625 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 396 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 1 459 | Stock Option (right to buy) |
2024-03-26 | Deck Kelly | Sell | 416 | Stock Option (right to buy) |
2024-03-20 | Deck Kelly | Sell | 16 777 | Stock Option (right to buy) |
INSIDER POWER |
---|
56.20 |
Last 100 transactions |
Buy: 3 248 725 | Sell: 1 114 859 |
ボリューム 相関
Inhibrx, Inc. 相関
10 最も負の相関 | |
---|---|
GDNR | -0.918 |
BTWN | -0.917 |
EZGO | -0.906 |
LUNA | -0.904 |
BRAC | -0.903 |
MLCO | -0.902 |
MLVF | -0.902 |
AVAC | -0.902 |
CBAY | -0.9 |
IIN | -0.899 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Inhibrx, Inc. 相関 - 通貨/商品
Inhibrx, Inc. 財務諸表
Annual | 2023 |
収益: | $1.80M |
総利益: | $609 000 (33.83 %) |
EPS: | $-5.12 |
FY | 2023 |
収益: | $1.80M |
総利益: | $609 000 (33.83 %) |
EPS: | $-5.12 |
FY | 2022 |
収益: | $2.18M |
総利益: | $-668 000 (-30.67 %) |
EPS: | $-3.62 |
FY | 2021 |
収益: | $7.13M |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.15 |
Financial Reports:
No articles found.
Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。